Long-Term Opioid Efficacy Act of 2018
This bill expands the authority of the Food and Drug Administration (FDA) to require post-approval studies or clinical trials with respect to controlled substances (e.g., opioids).
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2018-06-20 | IntroReferral | Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. | Senate |
| 2018-06-19 | Floor | Motion to reconsider laid on the table Agreed to without objection. | House floor actions |
| 2018-06-19 | Floor | On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5243) | House floor actions |
| 2018-06-19 | Floor | DEBATE - The House proceeded with forty minutes of debate on H.R. 5811. | House floor actions |
| 2018-06-19 | Floor | Considered under suspension of the rules. (consideration: CR H5243-5244) | House floor actions |
| 2018-06-19 | Floor | Mr. Walden moved to suspend the rules and pass the bill, as amended. | House floor actions |
| 2018-05-17 | Committee | Ordered to be Reported (Amended) by Voice Vote. | House committee actions |
| 2018-05-17 | Committee | Committee Consideration and Mark-up Session Held. | House committee actions |
| 2018-05-15 | IntroReferral | Referred to the House Committee on Energy and Commerce. | House floor actions |
| 2018-05-15 | IntroReferral | Introduced in House | Library of Congress |